Renbio

RenBio is a private, preclinical-stage biotech developing a disruptive DNA delivery platform called MYO Technology. The platform encodes therapeutic proteins or antibodies in DNA, which is administered via intramuscular injection and electroporation, instructing the patient's muscle to become a bioreactor for sustained, in vivo drug production. This approach seeks to overcome key limitations of traditional biologics, including frequent dosing, high manufacturing costs, and cold-chain logistics. The company, co-founded by renowned virologist Dr. David Ho, is initially targeting infectious diseases and metabolic conditions like obesity, with the goal of creating longer-lasting, more accessible therapies.

Make Your Own (MYO) Technology: A DNA-based platform using intramuscular injection and electroporation to deliver genetic blueprints, enabling a patient's own muscle cells to produce therapeutic proteins or antibodies in vivo for sustained effect.

RenBio competes in the advanced biologics delivery space against companies developing mRNA/LNP platforms (e.g., Moderna, BioNTech), viral vector gene therapy approaches, and other electroporation-based DNA delivery firms. Its differentiation hinges on demonstrating superior durability, safety, and cost-effectiveness compared to these alternatives for in vivo protein production.